

CDDF MULTI-STAKEHOLDER WORKSHOP ON IMPACT OF THE MICROBIOME ON CANCER GROWTH AND THERAPY

15-16 February 2019
Munich, Germany

The poster features a red circular graphic on the left containing text. To the right is a central illustration of a human silhouette surrounded by a circular cloud of colorful, multi-colored shapes representing a microbiome. Logos for CDDF and Tumorzentrum München (TZM) are positioned at the top right of the graphic area.

CDDF MULTI-STAKEHOLDER WORKSHOP

IMPACT OF THE
MICROBIOME ON
CANCER GROWTH
AND THERAPY

15-16 FEBRUARY 2019
MUNICH, GERMANY

ORGANIZED BY THE CANCER DRUG DEVELOPMENT FORUM
IN PARTNERSHIP WITH THE TUMOR CENTER MUNICH

FURTHER INFORMATION ON WWW.CDDF.ORG

Organized by CDDF and TZM



Key Contacts

Anissa Brennet (Association Coordinator, CDDF) : cddf@ecco-org.eu ; anissa.brennet@ecco-org.eu



CDDF MULTI-STAKEHOLDER WORKSHOP
**IMPACT OF THE MICROBIOME ON CANCER GROWTH
AND THERAPY**

15-16 FEBRUARY 2019
MUNICH, GERMANY

EVENT OUTLINE

The workshop on Impact of the Microbiome on Cancer Growth and Therapy is organized by the Cancer Drug Development Forum (CDDF) in cooperation with the Munich Tumour Centre (TzM), with the aim of enhancing the understanding of the human microbiome and its critical role in cancer growth and treatment. The workshop provides comprehensive insights into the human microbiome and its application to cancer research as well as valuable opportunities to establish network in the emerging microbiome field.

The first edition of the CDDF workshop on Impact of the Microbiome on Cancer Growth and Therapy will be held on 15 - 16 June 2018, in Munich, Germany and will offer small group lectures and interactive discussions to effectively exchange expertise and broaden perspectives. The lectures will focus on the links between the human microbiome and cancer with a special attention to inflammation and immune system.

During the workshop, participants will enhance their knowledge of the current and future development in the microbiome research and its clinical relevance. Most importantly, delegates will network with various players and experts in the emerging microbiome sector.

PROGRAMME COMMITTEE

Matthew Albert (Roche/Genentech, USA)
Phillip Dennis (AstraZeneca, USA)
Andreas Diefenbach (Charité – Universitätsmedizin Berlin, Germany)
Volkmar Nussler (CDDF/Tumor Center, Munich, Germany)
Giorgio Trinchieri (Center for Cancer Research/NCI/NIH, USA)
Heinz Zwierzina (CDDF/Innsbruck University Hospital, Austria)
Laurence Zitvogel (Gustave Roussy, France)

TARGET AUDIENCE

The target audience is a multi-disciplinary community of researchers, medical oncologists, nutritionists and other healthcare professionals, representatives from pharmaceutical, nutrition and biomedical industries, patient advocates, and students who have a keen interest in microbiome research.

WORKSHOP VENUE AND CO-ORGANIZER:

Klinikum Rechts der Isar
(Room Pavillion)
(Main Entrance: Einstein Strasse)
Ismaninger Str. 22
81675 Munich
Germany
www.med.tum.de

HEADQUARTERS HOTEL:

Courtyard by Marriott Munich City East
Orleansstraße 81-83
81667 München, Deutschland
t: +49 89 558 919 180

PROGRAMME

DAY 1 – FRIDAY 15 FEBRUARY 2019

14:00 – 14:15 Welcome

KEYNOTE LECTURE

14:15 Keynote lecture: Microbiome and Immune System in Cancer
[Laurence Zitvogel \(Gustave Roussy, France\)](#)

14:50 Crosstalk between Inflammation and the microbiome
TO BE ANNOUNCED

15:10 Identification of a genetic locus controlling bacteria-driven colitis and associated cancer through effects on innate inflammation
TO BE ANNOUNCED

15:30 Effects of non)antibiotics on the microbiome
[Georg Zeller \(EMBL Heidelberg, Germany\)](#)

15:50 **COFFEE BREAK**

16:20 Potential of fecal microbiota for early-stage detection of colorectal cancer
[Georg Zeller \(EMBL Heidelberg, Germany\)](#)

16:40 Crosstalk of the microbiome and epithelial cells
[Dirk Haller \(Technische Universität München, Germany\)](#)

17:00 Regulation of life span by the gut microbiome
[Dario Valenzano \(Max Planck Institute for Biology of Ageing, Germany\)](#)

17:20 Applying Systems-Biology to study the mechanistic interactions of the gut microbiota
[Naama Geva-Zatorsky \(Technion, Israel\)](#)

17:40 Gut microbiota-derived propionate reduces cancer cell proliferation in the liver
[Laura Bindels \(Université Catholique de Louvain, Belgium\)](#)

18:00 Microbiome restoration therapy in acute myeloid leukemia
TO BE ANNOUNCED

18:20 **End of day 1**

19:30 **Networking dinner**
Zum Franziskaner (Residenzstraße 9, 80333 Munich)

END OF DAY 1

DAY 2 – SATURDAY 16 FEBRUARY 2019

KEYNOTE LECTURE

- 09:30** Keynote lecture: Microbiome and Immunotherapy in Cancer
Giorgio Trinchieri (Center for Cancer Research/NCI/NIH, USA)
- 10:05** Interplay of innate lymphoid cells and the microbiota
Andreas Diefenbach (Charité – Universitätsmedizin Berlin, Germany)
- 10:25** Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment
TO BE ANNOUNCED
- 10:45** The Intra-tumoral bacterial flora - potential implications
Mark Tangney (University College Cork, Ireland)
- 11:05** **COFFEE BREAK**
- 11:35** Monoclonal microbials and cancer therapy
Mark Bodmer (Evelo Biosciences, USA)
- 11:55** Microbiota-based supplements – the future of cancer treatment?
Maria Vehreschild (University Hospital Cologne, DE)
- 12:15** Challenges in Regulating Microbiota
Anja Düchting (BfArM, DE)
- 12:35** Enhancement of Anti-Tumor Immunity via Targeted Alteration of the Microbiome
Bernat Olle (Vedanta Biosciences)

CLOSING REMARKS

- 12:55** Concluding remarks and discussion
- 13:15** **LUNCH & END OF THE MEETING**